Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb single-arm open-label study of olorofim for resistant invasive fungal infections
2017-001290-17Phase 2Completed
- Sponsor
- F2G
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olorofim in invasive mycoses, lomentosporiosis, allescheriosis and 1 more, sponsored by F2G. Primary endpoint: DRC-adjudicated overall response at Day 42. Started Feb 2018; status: completed.
02
Drugs
olorofim
03
Conditions
invasive mycoseslomentosporiosisallescheriosisinvasive aspergillosis (IA)
Beyond the preview
Go deeper on 2017-001290-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001290-17.